An interventional study of Questionnaire in Rectal Adenocarcinoma, LARS - Low Anterior Resection Syndrome and Rectal Resection, sponsored by University Hospital, Antwerp. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by University Hospital, Antwerp · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Rectal Neoplasms with a site in Belgium — 10 open to participants now, 20 under way, 4 of them phase 3. Rectal Neoplasms · Belgium.
Among the 56 studies in Rectal Neoplasms with a site in Belgium, this one is the 28th largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2024, is one of 13 with no phase, reaches primary completion later than 14 of the 19 other live ones, and was the 54th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →10 of the 56 studies in Rectal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
KU Leuven · Sites in Belgium
Ages 18+
Centre Hospitalier Universitaire Saint Pierre · Sites in Belgium
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
KU Leuven · Sites in Belgium
Ages 18+
Jules Bordet Institute · Sites in Belgium
Ages 70+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 19
First in 1993; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 156 across the 45 interventional studies, 188 across the 7 observational. Of the 34 that completed or were terminated, 5 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 56 have an industry lead sponsor. The 10 most frequent:
University Hospital, Antwerp is the lead sponsor of 243 studies on the registry; 66 are open to participants now.
University Hospital, Antwerp has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Rectal Neoplasms with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT04503694Jules Bordet InstituteNeoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 56 studies in Rectal Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
OBJECTIVE Low anterior resection syndrome (LARS) is a term for functional bowel complaints occurring after low anterior resection. Symptoms can range from faecal incontinence and frequent loose stools to urgency and incomplete emptying with great impact on quality of life. Little is known about the longitudinal evolution of LARS and the impact of different schedules of neoadjuvant chemoradiotherapy combined with surgery.
The investigators aim to investigate the incidence and evolution of functional bowel complaints in function of different neoadjuvant treatment regimens, type of surgery and adjuvant therapy in patients who undergo surgery for rectal cancer. The investigators focus on following objectives: evolution of LARS- and COREFO-scores per treatment regimen and their impact on work incapacity; identification of possible risk factors potentially related to functional outcome; monitoring and treatment of LARS.
METHODS This will be a multicentre prospective interventional study. The study population will consist of adult patients with rectal cancer, regardless of any neo-adjuvant therapy. Patients will be included for 5 years with a 2 year postoperative follow-up. Interim analysis will be made after 2 years of inclusion. Patients with intellectual disability or clinical colon obstruction are excluded. Automated online questionnaires including LARS and COREFO scores, incapacity for work and defecation quality will be sent at different time points (figure 1) using REDCap.
RESULTS and CONCLUSIONS Longitudinal change of LARS- and COREFO-scores will be visually summarized. Patient, disease or procedure specific risk factors will be assessed as well.
LARS is proven to be the principal postoperative problem after rectal surgery. If the investigators can predict the severity of LARS (minor or major LARS), this can be extremely helpful in deciding whether to perform a sphincter-sparing resection or a rectal amputation instead. Furthermore, the investigators want to offer perspective to patients who are susceptible to a disturbed postoperative bowel function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who undergo rectal resection without neo-adjuvant therapy
Other: Questionnaire
Patients who receive neo-adjuvant therapy before undergoing rectal surgery
Other: Questionnaire
Online questionnaire regarding LARS- and COREFO-scores, quality of defecation process, incapacity for work and initiation of treatment for potential LARS at different moments in time
The evolution of the COREFO-score (Colorectal Functional Outcome questionnaire) at 2 years after rectal surgery compared to baseline (absolute difference) will be examined
27 questions on 5-point Likert scale Higher score = worse bowel function
Time frame: 2 years from when rectal resection or stoma reversal was performed
Evolution of LARS-score (low anterior resection syndrome) at 2 years after rectal surgery compared to baseline (absolute difference)
0-20 = no LARS 21-29 = minor LARS 30-42 = major LARS
Time frame: 2 years from when rectal resection or stoma reversal was performed
The evolution of the LARS-score (low anterior resection syndrome) at 2 years after rectal surgery compared to baseline (relative difference) will be examined.
0-20 = no LARS 21-29 = minor LARS 30-42 = major LARS
Time frame: 2 years from when rectal resection or stoma reversal was performed
The evolution of the COREFO-score (Colorectal Functional Outcome questionnaire) at 2 years after rectal surgery compared to baseline (relative difference) will be examined
27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100)
Time frame: 2 years from when rectal resection or stoma reversal was performed
The evolution of the LARS-score (low anterior resection syndrome) in the absence of baseline data will be examined as well (absolute difference), comparing 2-year outcome to earliest results.
0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42)
Time frame: 2 years from when rectal resection or stoma reversal was performed
The evolution of the LARS-score (low anterior resection syndrome) in the absence of baseline data will be examined as well (relative difference), comparing 2-year outcome to earliest results.
0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42)
Time frame: 2 years from when rectal resection or stoma reversal was performed
The evolution of the COREFO-score (Colorectal Functional Outcome questionnaire) in the absence of baseline data will be examined as well (absolute difference), comparing 2-year outcome to earliest results.
27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100)
Time frame: 2 years from when rectal resection or stoma reversal was performed
The evolution of the COREFO-score (Colorectal Functional Outcome questionnaire) in the absence of baseline data will be examined as well (relative difference), comparing 2-year outcome to earliest results.
27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100)
Time frame: 2 years from when rectal resection or stoma reversal was performed
LARS-score (low anterior resection syndrome) score at diagnosis
0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42) LARS = low anterior resection syndrome Using a questionnaire Unit = mean score (0-42)
Time frame: At diagnosis = baseline
COREFO-score at diagnosis (Colorectal Functional Outcome questionnaire)
27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100) COREFO = Colorectal Functional Outcome questionnaire Using a questionnaire Unit = mean score (0-100)
Time frame: At diagnosis = baseline
LARS-score (low anterior resection syndrome) after neo-adjuvant therapy
0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42) LARS = low anterior resection syndrome Using a questionnaire Unit = mean score (0-42)
Time frame: After neo-adjuvant therapy (up to 6 months from baseline)
COREFO-score after neo-adjuvant therapy (Colorectal Functional Outcome questionnaire)
27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100) COREFO = Colorectal Functional Outcome questionnaire Using a questionnaire Unit = mean score (0-100)
Time frame: After neo-adjuvant therapy (up to 6 months from baseline)
LARS-score (low anterior resection syndrome) shortly prior to surgery when there is a delay of 4 or more weeks after finishing neoadjuvant therapy
0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42) LARS = low anterior resection syndrome Using a questionnaire Unit = mean score (0-42)
Time frame: 2 days prior to surgery
COREFO-score (Colorectal Functional Outcome questionnaire) shortly prior to surgery when there is a delay of 4 or more weeks after finishing neoadjuvant therapy
27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100) COREFO = Colorectal Functional Outcome questionnaire Using a questionnaire Unit = mean score (0-100)
Time frame: 2 days prior to surgery
LARS-scores (low anterior resection syndrome) postoperatively after 1 month, 3 months, 6 months, 1 year and 2 years
0-20 no LARS 21-29 minor LARS 30-42 major LARS (min 0 - max 42) LARS = low anterior resection syndrome Using a questionnaire Unit = mean score (0-42)
Time frame: Postoperatively after 1 month, 3 months, 6 months, 1 year and 2 years
COREFO-scores (Colorectal Functional Outcome questionnaire) postoperatively after 1 month, 3 months, 6 months, 1 year and 2 years
27 questions on 5-point Likert scale Higher score = worse bowel function (min 0 - max 100) COREFO = Colorectal Functional Outcome questionnaire Using a questionnaire Unit = mean score (0-100)
Time frame: Postoperatively after 1 month, 3 months, 6 months, 1 year and 2 years
Evolution of quality of defecation process
Visual analogue scale 0-10 0 = worst defecation ever 10 = best defecation ever
Time frame: 2 years after rectal resection or stoma reversal
Incapacity for work
Time (days) between date of start work incapacity and date back to work (if not yet retired)
Time frame: At diagnose (baseline), 2 days after radiotherapy, 1 week after chemotherapy and 1 month after rectal resection
Initiation of treatment for potential LARS (low anterior resection syndrome) during follow-up
Yes/no: * Dietary measures * Medication (probiotics, antidiarrheals, ...) * Pelvic floor physiotherapy * Transanal irrigation, rectal irrigation, enema * Neuromodulation (neurostimulator) * Other Calculating proportion of patients who received treatment for LARS
Time frame: Up to 2 years after rectal resection
Gender
Male, female, other
Time frame: Baseline
Year of birth
Year of birth
Time frame: Baseline
Age
Age at diagnosis and at surgery
Time frame: Baseline to date of surgery
Hospital admission data
Length of stay in days (date of admission for rectal resection until date of dismission)
Time frame: After rectal resection
Medical history
Smoking, diabetes mellitus, abdominal, cardiac, pulmonary (yes/no)
Time frame: Baseline
Anthropometry
Body mass index (kg/m²)
Time frame: Baseline
Tumor location
Distance in cm from recto-anal angle, based on MRI
Time frame: After restaging prior to surgery
Presence of lateral lymph nodes
Presence of lateral lymph nodes (yes/no)
Time frame: After restaging prior to surgery
cTNM
Clinical TNM classification of tumor: * T: tumor size * N: nodal involvement * M: metastasis
Time frame: After restaging prior to surgery
Percentage of rectal circumference involved
Percentage of rectal circumference involved: on imaging (CT/MRI), coloscopy or ultrasound-endoscopy
Time frame: After restaging prior to surgery
Circumferential resection margin
Circumferential resection margin (CRM; on MRI; measured from gland; in mm)
Time frame: After restaging prior to surgery
Neoadjuvant therapy
The eventual use of neoadjuvant therapy: radiotherapy (RT), chemotherapy (CT) (yes/no)
Time frame: From baseline to surgery
Radiotherapy dose
Radiotherapy dose (Gy)
Time frame: From baseline to surgery
Chemotherapy type and frequency
Certain type of chemotherapy, used for certain amount of cycles
Time frame: From baseline to surgery
Surgical approach
Surgical approach: * Open * Laparoscopy * Robot * Transanal (TaTME)
Time frame: At surgery
Configuration of anastomosis
Configuration of colorectal/coloanal anastomosis: * End-to-End * Side-to-End * End-to-Side * Side-to-Side
Time frame: At surgery
Manual or stapled anastomosis
Manual or stapled anastomosis
Time frame: At surgery
Conversion
Conversion during surgery: * Robot to laparoscopy (yes/no) * Laparoscopy to open (yes/no)
Time frame: At surgery
Diverting ileostomy
Use of a diverting ileostomy (yes/no)
Time frame: At surgery
Baseline CEA
Baseline CEA: Carcinoembryonic antigen (µg/L)
Time frame: At baseline
Histology type
Histology type of tumor (adenocarcinoma, squamous cell carcinoma, neuro-endocrine tumor etc.)
Time frame: After surgery
Tumor differentiation
Well differentiated Moderately differentiated poorly differentiated
Time frame: After surgery
Tumor perforation
Tumor perforation on histology (yes/no)
Time frame: After surgery
Radical resection
Radical resection: R0, R1, R2
Time frame: After surgery
pTNM
Pathological TNM classification of tumor * T: tumor size * N: nodal involvement * M: metastasis
Time frame: After surgery
Disease free interval
Disease free interval: the period of time between the primary treatment of a malignancy and the first sign of tumor recurrence (in months)
Time frame: Up to 2 years after rectal resection
Type of complication
Type of complication: * Urinary tract infection * Pulmonary complications * Surgical site infection * Intra-abdominal collections/abscess * Eventration/evisceration * Ileus * Small bowel obstruction * Anastomotic leakage * Deep venous thrombosis * Postoperative bleeding * Acute renal failure * High output ileostomy * Other stoma related complications * Other (yes/no)
Time frame: After rectal resection during admission
Early complications
Early complications: before 30 days after surgery
Time frame: Between surgery and 30 days after surgery
Late complications
Late complications: more than 30 days after surgery
Time frame: From 30 days after surgery up to 2 years after surgery
Anastomotic leakage
Definition of anastomotic leakage: * Clinically manifest insufficiency of the anastomosis leading to a clinical state requiring treatment, diagnosed in accordance with surgical practice guidelines by a senior surgeon (no additional or systematic routine iconography nor colonoscopy) * Radiological evidence of anastomotic leakage if the patient is clinically symptomatic. Fistulas communicating with the anastomosis on CT scan are classified as AL together with presacral abscesses if extravasation of the colonic contrast is visible on radiological imaging (ref. SAFE 2019 Clinical Investigation Plan) (yes/no)
Time frame: Up to 3 months after surgery
Clavien-Dindo classification
Clavien-Dindo classification (grade 0, I, II, IIIa, IIIb, IVa, IVb, V): Grade I: Minor deviation from normal course; no drugs or interventions needed (only supportive care). Grade II: Requires pharmacological treatment (e.g. antibiotics, blood transfusion, TPN). Grade III: Requires surgical, endoscopic, or radiological intervention IIIa: without general anesthesia IIIb: with general anesthesia Grade IV: Life-threatening complication requiring ICU care IVa: single-organ dysfunction IVb: multi-organ dysfunction Grade V: Death
Time frame: After admission for rectal resection
CCI-score
CCI-score: comprehensive complication index (score from 0-100 calculated with online calculator: https://www.cci-calculator.com/cci-calculator)
Time frame: After admission for rectal resection
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Aug 2029, 60 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 60 months is above that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Antwerp →